

Distinct nicotinic acetylcholine receptors in dorsal and ventral striatum: Basis for novel therapies of Parkinson's disease

<https://www.neurodegenerationresearch.eu/survey/distinct-nicotinic-acetylcholine-receptors-in-dorsal-and-ventral-striatum-basis-for-novel-therapies-of-parkinsons-disease/>

Principal Investigators

Salminen Outi

Institution

University of Helsinki

Contact information of lead PI

Country

Finland

Title of project or programme

Distinct nicotinic acetylcholine receptors in dorsal and ventral striatum: Basis for novel therapies of Parkinson's disease

Source of funding information

Academy of Finland

Total sum awarded (Euro)

€ 433,299

Start date of award

01/09/2013

Total duration of award in years

4

Keywords

Research Abstract

Parkinson's disease is levodopa. However, levodopa treatment is plagued by adverse effects, especially dyskinesias that affect the whole body. Presently, there is no effective drug therapy against dyskinesias. In animal models, it has been shown that nicotinic drugs could be effective in treating dyskinesias. This study aims at clarifying what are the mechanisms of levodopa-induced dyskinesias and, further, how nicotine elicits its antidyskinetic effect. The aim of the

proposed research is to build the basis for development of improved drug therapy for currently poorly treated aspects of Parkinson's disease.

Further information available at:

Types:

Investments < €500k

Member States:

Finland

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A